Pulmonx (NASDAQ:LUNG) Stock, Quote.Headers.trade-ideas

Pulmonx

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Earnings

News

Penny Stocks

Health Care

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

ENOV

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LUNG

The medical info systems industry is set to thrive in the second half of 2024 due to the growing demand for contactless services. The industry witnessed exponential growth during the pandemic era. Even in the post-pandemic period, remote healthcare, a paperless environment and distant treatment paved the way for digital services.

5 Medical Info Systems Stock to Buy for a Stable Portfolio

C.H. Robinson Worldwide - logo

Intraday Update

Movers

ASPN

BPMC

CHRW

CVNA

ENVX

GKOS

ITRI

LNTH

MRNA

NOVA

PRDO

QCOM

TROX

C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday

ACVA

AGRX

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

ATNI

BBLG

BELFA

BZFD

DOCN

DPRO

EAST

ETSY

EZFL

GBNH

GSHD

INDV

KTOS

LCID

LRHC

MATV

MGPI

MNPR

MNTS

NVAX

NVDA

OCUL

QTWO

RELY

RILY

RIVN

ROOT

RXRX

SMCI

SNPS

SNPX

TRUE

VERO

Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Pulmonx Corp

ISPC

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

KSCP

Thursday,&nbsp;Moderna&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)&nbsp;unveiled key updates at its annual R&amp;D Day by reducing annual R&amp;D spending by $1.1 billion by 2027, enabling a focus on <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40834547/moderna-outlines-post-covid-roadmap-cuts-research-budget-forecasts-2025-sales-below-expectations" rel="noreferrer noopener">ten prioritized products</a>.
The company expects R&amp;D expenses to fall from $4.8 billion in 2024E to $3.6 billion—$3.8 billion in 2027.
The strategy, expanding its portfolio into oncology and rare diseases, positions Moderna to deliver ten product approvals within the next three years.
Oppenheimer downgraded Moderna stock from Outperform to Perform and <a target="_blank" href="https://www.benzinga.com/quote/MRNA/analyst-ratings" rel="noreferrer noopener">removed the price target</a>.
Oppenheimer analyst writes that with a restructured R&amp;D budget, Moderna&#8217;s non-respiratory assets will play a larger role in shaping the pipeline and face increased pressure to reach commercialization.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40754517/modernas-investigational-mpox-vaccine-more-effective-than-current-approved-shot-animal-study-show" rel="noreferrer noopener">Moderna&#8217;s Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows</a>.
RBC Capital Market decreased the price target from $90 to $75 while maintaining the Sector rating.
The analyst notes the COVID-19 vaccine maker pushed its breaking-even event by two years to 2028.
The analyst remains confident in Moderna&#8217;s cancer vaccine and the potential of its broader platform over the long term. However, near-term challenges continue to be seen, such as declining COVID-19 vaccination rates and the gradual uptake of the respiratory syncytial virus (RSV) vaccine.
Needham&#8217;s analyst highlights substantial commercial and competitive challenges in the respiratory vaccine market across all indications. Investors appear to view cytomegalovirus (CMV) as a less significant commercial opportunity, while the rare disease programs, including MMA and PA, are expected to have only modest peak sales potential, estimated at around $500 million.
The analyst says the INT Oncology program, developed in partnership with Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), offers the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39138772/moderna-merck-reveal-three-year-data-for-individualized-cancer-therapy-in-high-risk-melanoma-pati" rel="noreferrer noopener">most upside potential</a>. However, progress has been slow, and revenue from this program is unlikely to materialize before 2027 or later. Needham maintains the Hold rating.
William Blair notes that Moderna&#8217;s pattern of issuing high financial expectations, followed by lowered guidance, has negatively impacted the company&#8217;s stock.
Since cutting its 2024 revenue forecast during its second-quarter earnings 2024 call, the stock has <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40139012/moderna-stock-trading-lower-on-dismal-guidance-analysts-cuts-price-targets-noting-c" rel="noreferrer noopener">dropped approximately 40%</a>.
The analyst highlights that although Moderna has now pushed back its goal of breaking even to 2028, it will still need to double its revenue from the projected $3.0 billion-$3.5 billion in 2024 to $6.0 billion by 2028 to achieve breakeven along with reduced operating costs and streamlined COGS.
Piper Sandler reiterates the Overweight rating on Moderna but lowers the price target to $115 from $157.
Price Action: MRNA stock closed lower by 2.01% to $68.28 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40858554/chevron-takes-step-towards-greener-shipping-details" target="_blank" rel="noreferrer noopener">Chevron Takes Step Towards Greener Shipping: Details</a>.</li>
</ul>
Photo via <a href="https://commons.wikimedia.org/wiki/File:Moderna_COVID-19_vaccine_%282021%29_F.jpg">Wikimedia Commons</a>

Analyst Color

Biotech

Large Cap

Downgrades

Price Target

Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target

The road to cannabis legalization has been long, and the journey isn't over yet. Currently, 46 states have legalized or decriminalized marijuana to some degree, but it remains illegal at the federal level.
However, Americans are getting closer to the prize thanks to a proposal to reclassify marijuana from a Schedule I to a Schedule III drug. What does this mean for the pre-roll industry? They've already proven to be a successful addition to the industry, with <a href="https://www.greenmarketreport.com/pre-roll-price-check-how-the-evolving-market-affects-prices-and-sales/">pre-rolls now accounting for 15% of the market</a> as supply increases and prices decline. Here's what you need to know about potential benefits and how to strategize accordingly.
<h2 class="wp-block-heading">What Does Reclassification Mean for Marijuana?</h2>
Since the Controlled Substances Act (CSA) was enacted in 1970, cannabis has been<a href="https://www.justice.gov/opa/pr/justice-department-submits-proposed-regulation-reschedule-marijuana"> classified as a Schedule I drug</a>. This puts it in the <a href="https://www.dea.gov/drug-information/drug-scheduling">same category as illicit drugs</a> like heroin, LSD and ecstasy and defines it as a drug with high potential for abuse and "no currently accepted medical use."&nbsp;
The Justice Department, recognizing the views of the Department of Health and Human Services (HHS) that marijuana does have <a href="https://www.dea.gov/sites/default/files/2024-05/Scheduling%20NPRM%20508.pdf">accepted medical uses</a>, announced in May that the attorney general submitted a proposal to <a href="https://www.justice.gov/opa/pr/justice-department-submits-proposed-regulation-reschedule-marijuana">reclassify marijuana</a> as a Schedule III drug.
If approved, this proposal would place marijuana in a category alongside prescription<a href="https://www.dea.gov/drug-information/drug-scheduling"> drugs like Tylenol with codeine</a>, testosterone and anabolic steroids.&nbsp;
Schedule III drugs not only have accepted medical uses but also have a lower potential for abuse than Schedule I and II drugs, along with moderate to low potential for dependence (physical and psychological).
How long will it take for rescheduling to occur? There's no set timeline, but the Justice Department started the process by submitting the proposal and <a href="https://www.justice.gov/opa/pr/justice-department-submits-proposed-regulation-reschedule-marijuana">notifying the public</a>.
From there, the public can submit commentary to the Drug Enforcement Agency (DEA), which the agency will consider before making and publishing a final ruling concerning scheduling. The <a href="https://www.forbes.com/sites/dariosabaghi/2024/05/22/dea-publishes-proposed-rules-to-reschedule-marijuana/">62-day window for public commentary</a> ended July 22, 2024, but there is no timeline for review.
<h2 class="wp-block-heading">New Financial Landscape</h2>
The major benefit of reclassification is that cannabis will no longer be subject to Internal Revenue Service (IRS) Code Section 280E. This <a href="https://www.irs.gov/newsroom/irs-marijuana-remains-a-schedule-i-controlled-substance-internal-revenue-code-section-280e-still-applies">section of the tax code</a> essentially states that businesses selling Schedule I or II substances cannot take deductions or credits for any part of their business, including ordinary and necessary expenses.
<h3 class="wp-block-heading">Financial Benefits Related to Section 280E</h3>
Even if your pre-roll business operates legally within your state, this rule means you pay more taxes than the average business.&nbsp;
In 2022, this increased tax burden equated to over <a href="https://www.prnewswire.com/news-releases/economic-analysis-indicates-cannabis-industry-paid-1-8-billion-in-excess-taxes-in-2022--301817848.html">$1.8 billion in excess taxation</a> across the cannabis industry, with tax rates commonly exceeding 70%. As a result, less than 25% of cannabis companies reported profitability.
If marijuana becomes a Schedule III substance, Section 280E will no longer apply, which will have a major impact on how you file taxes. You can claim deductions and credits that significantly reduce your tax burden, allowing you to retain much more income.
In addition, you could file amended tax returns to reclaim deductions for any returns within the statute of limitations. The scope will depend on the effective date and whether it's retroactive.
<h3 class="wp-block-heading">Is Increased Access to Banking Services Possible?</h3>
Currently, banking organizations deem cannabis businesses as high risk for impacting FDIC insurance status. Will that change under the Schedule III classification, which applies to legal prescription substances?
The answer is maybe. It's important to understand that doctor recommendations for cannabis that are legal at the state level are not the same as federally legal prescriptions, and this presents some barriers.
Research and development could lead to the formulation of prescription cannabis drugs that go through the vetting process to be approved by the FDA. This approval would mean they could be sold in pharmacies instead of dispensaries.&nbsp;
In that case, there is some potential for legal validation that might sway banking institutions. However, that's a lot of ifs, so the value of this possible benefit remains to be seen.
<h3 class="wp-block-heading">Immediate and Long-Term Benefits for Businesses</h3>
With a reduced tax burden, cannabis businesses will immediately retain more income. This extra cash could be funneled into product development, equipment upgrades, higher-quality inventory and expansion.
It may also draw investors and encourage new business launches, increasing competition that drives access, innovation and consumer choice.&nbsp;
Finally, opportunities to develop FDA-approved prescription drugs could help legitimize the industry, potentially attracting new customers, increasing access to banking services and bringing cannabis one step closer to federal legalization.
<h3 class="wp-block-heading">Financial Benefits for Consumers</h3>
Businesses won't be alone in enjoying financial benefits if marijuana is reclassified. When the tax burden on sellers is reduced, savings could be passed along to consumers.
Consider that a typical <a href="https://worldpopulationreview.com/state-rankings/cigarette-prices-by-state">pack of 20 cigarettes</a> costs about $8 in the U.S., or about $0.40 per cigarette. Since a pre-roll joint costs anywhere from $5-$20 or more, a 20-pack could set consumers back $200.
<h2 class="wp-block-heading">A New Market for Products and Consumers</h2>
Cannabis has been widely recognized (including by <a href="https://www.dea.gov/sites/default/files/2024-05/Scheduling%20NPRM%20508.pdf">HHS and the Justice Department</a>) as having greater medical value and less potential for abuse and dependence than suggested by its current CSA classification. Reclassification to Schedule III would open the door to a range of benefits for cannabis businesses and consumers.
<h3 class="wp-block-heading">New Products</h3>
One of the greatest potential detriments of marijuana being classified as a Schedule I substance is that opportunities for research and development have been severely restricted. The <a href="https://pharmanewsintel.com/features/barriers-to-medical-research-constructed-by-federally-controlled-substance-scheduling-and-classification">hurdles required to gain approval</a> for research are cumbersome.
Researchers must register with the DEA and gain approval from an institutional review board. This alone can take years, but the added difficulty of obtaining grant funding is scarce.
Even if researchers overcome these challenges, most lab facilities don't meet DEA standards for security and must undergo significant and expensive modification. Then, there are the difficulties of legally requesting and obtaining Schedule I substances for research purposes.
In other words, researching everything from the makeup of different strains to the effects of different cannabinoids on the human body is exceedingly difficult.&nbsp;
Reclassification would loosen restrictions and open the door to new research and development, potentially resulting in greater understanding, new products and increased quality.
<h3 class="wp-block-heading">New Customers</h3>
Reclassification of marijuana stands to benefit not only businesses but consumers as well. Existing customers could enjoy greater product diversity, efficacy, and cost reduction.
It might also attract new customers who may currently hesitate to try medical or recreational marijuana. This, in turn, could increase demand industrywide, and there's some potential for increased interstate commerce.&nbsp;
Businesses intent on expansion will want to grow their loyal customer base before new competition floods the market.
<h2 class="wp-block-heading">Innovation and Consistency</h2>
Because cannabis legislation varies from state to state, regulations are somewhat spotty. However, with greater research and development potential, likely leading to new product innovation and increased competition, quality, consistency, and compliance will become more important.
How can your pre-roll business remain competitive? You can start by implementing rigorous quality controls, seeking certification, offering transparency and choosing like-minded vendors like HARA Supply.
<h2 class="wp-block-heading">Reclassification Is Good for Businesses and Consumers</h2>
Although it's unclear when the reclassification of marijuana from a Schedule I to a Schedule III drug could be approved, those in the pre-roll industry must prepare for the changes it could bring about.&nbsp;
With opportunities to benefit from a reduced tax burden, increased product development and new customers, you stand to gain a lot, but only if you prepare for the probable increase in competition.
Capitalizing on marijuana reclassification means launching strategic initiatives to position your business for future success. HARA Supply is the reliable, established pre-roll supplier you need. Contact us now to learn more.

Cannabis

Schedule III Classification Offers New Opportunities For The Pre-Roll Industry

Hartford Finl Servs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) has outperformed the market over the past 10 years by 1.02% on an annualized basis producing an average annual return of 11.81%. Currently, Hartford Finl Servs Gr has a market capitalization of $33.80 billion. 
Buying $100 In HIG: If an investor had bought $100 of HIG stock 10 years ago, it would be worth $306.97 today based on a price of $115.36 for HIG at the time of writing.
<h3>Hartford Finl Servs Gr's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726263068_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Hartford Finl Servs Gr Stock In The Last 10 Years

Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) has outperformed the market over the past 5 years by 13.57% on an annualized basis producing an average annual return of 26.88%. Currently, Riot Platforms has a market capitalization of $2.19 billion. 
Buying $100 In RIOT: If an investor had bought $100 of RIOT stock 5 years ago, it would be worth $339.62 today based on a price of $7.23 for RIOT at the time of writing.
<h3>Riot Platforms's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726263063_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RIOT

Here's How Much $100 Invested In Riot Platforms 5 Years Ago Would Be Worth Today

Ibrahim Kalin, head of Turkey&#8217;s National Intelligence Agency, met with representatives from the Palestinian militant group Hamas in Ankara, Turkey&#8217;s capital, to discuss the negotiations <a href="https://www.benzinga.com/news/global/24/08/40608668/nine-palestinians-killed-as-israeli-forces-press-into-west-bank">for a cease-fire</a> in Gaza, according to media reports.
 Kalin met with a delegation from the Hamas political bureau leadership, Turkish news channel TRT Haber said, citing Turkish security sources, Reuters reported.
Turkey denounced Israel&#8217;s assault on Gaza. Turkey&#8217;s intelligence agency has been in contact with those involved in the conflict — Hamas, Israel, Qatar and the U.S. — as it carries out intensive diplomacy for a ceasefire in Gaza, TRT Haber said.
The war between Israel and Hamas began Oct. 7, 2023, when Hamas attacked Israel, killing 1,200 people and taking about 250 hostages, according to Israeli tallies.
Read Also: <a href="https://www.benzinga.com/government/24/03/37464565/gaza-cease-fire-by-ramadan-hopes-fade-biden-sends-special-envoy-to-lebanon">Gaza Cease-Fire By Ramadan Hopes Fade: Biden Sends Special Envoy To Lebanon</a>
Israel&#8217;s subsequent assault on Gaza has killed more than 41,000 Palestinians, according to its health ministry.
International mediators last week completed a new proposal aimed at forming a<a href="https://www.benzinga.com/news/24/09/40673642/israel-rocked-by-protesters-call-for-immediate-ceasefire-after-hostage-deaths" target="_blank" rel="noreferrer noopener">&nbsp;cease-fire deal&nbsp;</a>between Israel and Hamas as Israel's Prime Minister&nbsp;Benjamin Netanyahu&nbsp;refuses to cede control of Gaza's border with Egypt.
Israel's military and Hamas temporarily paused fighting <a href="https://www.benzinga.com/government/24/08/40639831/israel-hamas-to-pause-fighting-in-gaza-so-that-640-000-children-can-get-vaccinated-official">in the Gaza Strip</a> for three days a couple of weeks ago to allow about 640,000 children to get vaccinated against polio.
Price Action: Aerospace and defense stocks saw gains and losses on Friday as talks to end the fight take place.
<ul>
<li>Lockheed Martin Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) edged up 0.29% to close at $569.91</li>
<li>Boeing Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) slipped 3.69% to end the trading day at $156.77</li>
<li>Northrup Grumman&nbsp;Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) gained 0.24% to close at $519.78</li>
</ul>
Oil stocks traded up:
<ul>
<li>BP p.l.c.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) gained 0.82% to close at $31.84</li>
<li>Equinor ASA&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>) rose 1.05% to close at $25.09</li>
<li>Suncor Energy Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SU#NYSE">SU</a>) went up 0.41% to finish the trading day at $36.44</li>
</ul>
Read Now: • <a href="https://www.benzinga.com/markets/asia/24/02/37081429/international-criminal-court-raises-alarm-over-israeli-rafah-operations-urges-justice-for-war-crimes">International Criminal Court Raises Alarm Over Israeli Rafah Operations, Urges Justice For War Crimes</a>
Photo: Shutterstock

Government

Global

EQNR

Turkey's Spy Chief Meets With Hamas To Discuss Cease-Fire In Gaza: Reports

Across the recent three months, 15 analysts have shared their insights on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $78.47, a high estimate of $100.00, and a low estimate of $41.00. This current average has decreased by 3.52% from the previous average price target of $81.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1726261257_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Apellis Pharmaceuticals's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$57.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$83.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$41.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$74.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$96.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$83.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$66.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Akash Tewari</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$77.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Apellis Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Apellis Pharmaceuticals's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/APLS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Apellis Pharmaceuticals analyst ratings.</a>
<h2>Unveiling the Story Behind Apellis Pharmaceuticals</h2>
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
<h3>Financial Milestones: Apellis Pharmaceuticals's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Apellis Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 110.26% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Apellis Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -18.86%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Apellis Pharmaceuticals's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -14.18%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Apellis Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -4.34%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Apellis Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 1.8. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLS

Analyst Scoreboard: 15 Ratings For Apellis Pharmaceuticals

16 analysts have shared their evaluations of Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $111.5, along with a high estimate of $214.00 and a low estimate of $60.00. This current average has decreased by 18.06% from the previous average price target of $136.07. 
<img src="https://www.benzinga.com/files/images/story/2024/1726261232_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Moderna by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$110.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Tyler Van Buren</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$75.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$70.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Michael Yee</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$65.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Yifeng Liu</td>
<td>HSBC</td>
<td>Announces</td>
<td>Hold</td>
<td>$82.00</td>
<td>-</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$88.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Emmanuel Papadakis</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$90.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$178.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$157.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$214.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>In-Line</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Moderna. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Moderna compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Moderna's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Moderna's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/MRNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Moderna analyst ratings.</a>
<h2>About Moderna</h2>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
<h3>Moderna: Delving into Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Moderna's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -30.06%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Moderna's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -578.73%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Moderna's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -10.43%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Moderna's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -7.89%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Moderna's debt-to-equity ratio is below the industry average. With a ratio of 0.11, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

16 Analysts Have This To Say About Moderna

Providing a diverse range of perspectives from bullish to bearish, 20 analysts have published ratings on Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $71.85, a high estimate of $81.00, and a low estimate of $64.00. This upward trend is evident, with the current average reflecting a 3.58% increase from the previous average price target of $69.37.
<img src="https://www.benzinga.com/files/images/story/2024/1726261216_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Fortinet by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatima Boolani</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$76.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Fatima Boolani</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$66.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$75.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Yi Fu Lee</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Brad Zelnick</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$75.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Dan Bergstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$72.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$76.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Roger Boyd</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$64.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$72.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$68.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Fatima Boolani</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Shaul Eyal</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Buy</td>
<td>$75.00</td>
<td>-</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$69.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$70.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Raymond McDonough</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$81.00</td>
<td>$81.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Fortinet. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Fortinet compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Fortinet's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Fortinet's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FTNT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Fortinet analyst ratings.</a>
<h2>Get to Know Fortinet Better</h2>
Fortinet is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, zero-trust access, and security operations. The firm derives a majority of its revenue through sales of its subscriptions and support-based business. The California-based firm has more than 700,000 customers across the world.
<h3>Understanding the Numbers: Fortinet's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Fortinet's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 10.95%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Fortinet's net margin excels beyond industry benchmarks, reaching 26.48%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Fortinet's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 504.05% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Fortinet's ROA stands out, surpassing industry averages. With an impressive ROA of 4.83%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 3.45, caution is advised due to increased financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FTNT

Deep Dive Into Fortinet Stock: Analyst Perspectives (20 Ratings)

Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) has outperformed the market over the past 5 years by 17.75% on an annualized basis producing an average annual return of 31.06%. Currently, Moderna has a market capitalization of $26.16 billion. 
Buying $1000 In MRNA: If an investor had bought $1000 of MRNA stock 5 years ago, it would be worth $4,004.69 today based on a price of $68.05 for MRNA at the time of writing.
<h3>Moderna's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726261215_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Moderna Stock In The Last 5 Years

Qualcomm (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) has outperformed the market over the past 5 years by 3.03% on an annualized basis producing an average annual return of 16.34%. Currently, Qualcomm has a market capitalization of $186.65 billion. 
Buying $1000 In QCOM: If an investor had bought $1000 of QCOM stock 5 years ago, it would be worth $2,149.28 today based on a price of $167.55 for QCOM at the time of writing.
<h3>Qualcomm's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726261210_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today

Citigroup analyst Steven Zaccone maintains RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) with a Buy and raises the price target from $340 to $355.

Citigroup Maintains Buy on RH, Raises Price Target to $355

WIIM

XCUR

Exicure shares are trading higher after the company entered into debt-for-equity exchange agreements.

Planet Image Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YIBO#NASDAQ">YIBO</a>) reported quarterly earnings of $0.08 per share. This is a 11.11 percent decrease over earnings of $0.09 per share from the same period last year. The company reported $77.26 million in sales this quarter. This is a 4.12 percent increase over sales of $74.20 million the same period last year.

YIBO

Planet Image Intl H1 EPS $0.08 Down From $0.09 YoY, Sales $77.26M Up From $74.20M YoY

Gores Holdings IX, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHIX#NASDAQ">GHIX</a>) (the "Company") today announced that it received a delinquency notification letter (the "Notice") from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") on September 9, 2024 due to the Company's non-compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") as a result of the Company's failure to file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 (the "Q2 2024 Form 10-Q"). The Listing Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Notice has no immediate effect on the listing of the Company's securities on Nasdaq. However, if the Company fails to timely regain compliance with the rule, the Company's securities will be subject to delisting from Nasdaq.
The Notice provides that the Company has 60 calendar days to submit a plan to Nasdaq to regain compliance; if the plan is accepted, Nasdaq can grant an exception of up to 180 days from the due date of the Q2 2024 Form 10-Q, or until February 10, 2025, to regain compliance.

GHIX

Gores Holdings IX Receives Receipt Of Nasdaq Listing Delinquency Notification Letter

Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) CEO and co-founder Alex Karp didn't hold back when discussing how the company could help military governments in a recent interview ahead of a presentation<a href="https://www.benzinga.com/topic/artificial-intelligence"> on artificial intelligence.</a>
What Happened: Palantir may be one of the most hard-to-explain companies. Yet, it is now part of the<a href="https://www.benzinga.com/markets/equities/24/09/40769921/palantir-stock-soars-in-monday-premarket-whats-driving-the-surge"> S&amp;P 500 Index.</a>
Karp highlighted the company's government segment and what <a href="https://www.benzinga.com/topic/2024-presidential-election">the 2024 election</a> means for Palantir.
Companies need processes to help translate what data and language models mean. That&#8217;s where Palantir comes in, Karp <a href="https://x.com/SaraEisen/status/1834270110384623823">said</a> on CNBC.
"We figured this out by doing work for the U.S. government," he added. See below.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Alex Karp: "I support: if you touch an American, we will inflict pain on you for generations" he calls out both political parties on this <a href="https://twitter.com/PalantirTech?ref_src=twsrc%5Etfw">@PalantirTech</a> <a href="https://t.co/1Jv9MbKX1d">https://t.co/1Jv9MbKX1d</a>
&mdash; Sara Eisen (@SaraEisen) <a href="https://twitter.com/SaraEisen/status/1834270110384623823?ref_src=twsrc%5Etfw">September 12, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
If you want to kill your adversary on the battlefield, "you need a way of processing the raw resources," Karp said.
When it comes to government contracts, Karp didn't seem to worry about the 2024 election winner being either Ex-President Donald Trump or Vice President Kamala Harris.
"We embody people who support both Trump and Harris,&#8221; he said, claiming to be an &#8220;unhappy radical Democrat.&#8221; 
Karp also offered his take on what U.S. policy should be when it comes to retaliation for attacks on American troops.
"If you touch an American, we will inflict pain on you for generations,&#8221; he said.
Read Also: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40795608/palantirs-s-p-500-journey-rebel-tech-giant-transforms-into-frankenstein-monster-powere">Palantir&#8217;s S&amp;P 500 Journey: Rebel Tech Giant Transforms Into &#8216;Frankenstein Monster Powered By Freak Show Leader&#8217;</a>
What's Next: Karp said the S&amp;P 500 inclusion comes after years of complaints against the company. However, he stopped short of celebrating the moment.
"Our job is to show and not tell," Karp said.
Palantir could be worth 10 times more in the future than what it is today, he added.
PLTR Price Action: Palantir stock was up 2% to $35.59 on Friday. The stock hit a new 52-week high of $36.01 in Friday's trading session. Palantir stock is up over 110% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/08/40172453/palantir-q2-earnings-revenue-beat-eps-beat-customer-count-up-41-driven-by-strength-in-us-commercial">Palantir Q2 Earnings: Revenue Beat, EPS Beat, Customer Count Up 41% Driven By Strength In US Commercial</a></li>
</ul>
Image: Flickr

Management

PLTR

Palantir CEO Offers 'Radical' Take On National Security: 'Touch An American And We'll Inflict Pain On You For Generations'

Axis Capital Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXS#NYSE">AXS</a>) short percent of float has fallen 7.49% since its last report. The company recently reported that it has 1.18 million shares sold short, which is 1.73% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.7 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Axis Capital Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726260321_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Axis Capital Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Axis Capital Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Axis Capital Holdings's peer group average for short interest as a percentage of float is 1.93%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Axis Capital Holdings's Recent Short Interest

Seagate Tech Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STX#NYSE">STX</a>) short percent of float has risen 3.58% since its last report. The company recently reported that it has 11.48 million shares sold short, which is 6.66% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.36 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Seagate Tech Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726260316_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Seagate Tech Hldgs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Seagate Tech Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Seagate Tech Hldgs's peer group average for short interest as a percentage of float is 7.96%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Seagate Tech Hldgs's Recent Short Interest

EVgo's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NYSE">EVGO</a>) short percent of float has fallen 4.8% since its last report. The company recently reported that it has 26.20 million shares sold short, which is 26.16% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.8 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>EVgo Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726260311_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for EVgo has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing EVgo's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, EVgo's peer group average for short interest as a percentage of float is 11.11%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

EVGO

Peering Into EVgo's Recent Short Interest

SBRA, GH and CRBU are among after hour movers

Pulmonx: Low Bar For Q2 Earnings

Lake Street analyst Frank Takkinen reiterated a Buy rating on Pulmonx (LUNG – Research Report) today and set a price target of $12.00. The company'...

Lake Street Remains a Buy on Pulmonx (LUNG)

Pulmonx GAAP EPS of -$0.39

Pulmonx Corporation (LUNG) Q2 2024 Earnings Call Transcript

Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Pulmonx (LUNG – Research Report) today and set a price target of $10.00. The compan...

Wells Fargo Remains a Hold on Pulmonx (LUNG)

Canaccord Genuity analyst John Young CFA has maintained their bullish stance on LUNG stock, giving a Buy rating on August 1. John Young CFA has giv...

Buy Rating Affirmed for Pulmonx: Strong Growth and Promising Clinical Advancements

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on Pulmonx (LUNG – Research Report), with a price target of $12...

Pulmonx (LUNG) Gets a Buy from Lake Street

In a report released on September 6, Larry Biegelsen from Wells Fargo maintained a Hold rating on Pulmonx (LUNG – Research Report). The company's s...

Wells Fargo Reaffirms Their Hold Rating on Pulmonx (LUNG)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on OptimizeRx (OPRX – Research Report) and Pulmonx (LUN...

Wall Street Analysts Are Bullish on Top Healthcare Picks

CIFR

CRBU

GREE

LBPH

MRSN

MRVI

OPRX

SBRA

SIGA

Press Releases

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024

Pulmonx Reports First Quarter 2024 Financial Results

Financing

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024

Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference

Pulmonx Reports Second Quarter 2024 Financial Results

Pulmonx to Present at the 2024 Wells Fargo Healthcare Conference

Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference

Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Pulmonx

Pulmonx (LUNG) Forecast

Pulmonx (NASDAQ:LUNG) Stock, Quote.Headers.trade-ideas